Diffuse Midline Glioma, H3 K27-Altered
generalA diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.
11
Centers
23
Active Trials
—
Cancer Funding
Specific Cancer Types(1)
| Name | Centers |
|---|---|
| Recurrent Diffuse Midline Glioma, H3 K27-Altered | 11 |
Top Centers for Diffuse Midline Glioma, H3 K27-Altered(11)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive High-Volume Research Center | 75.0 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 52.5 |
| 3 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 52.5 |
| 4 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 52.5 |
| 5 | NCI Comprehensive Active Research Program | 52.5 |
| 6 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 52.5 |
| 7 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 52.5 |
| 8 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 52.5 |
| 9 | University of Illinois Cancer CenterChicago, IL Active Research Program | 52.5 |
| 10 | Boston University Cancer CenterBoston, MA Active Research Program | 52.5 |
| 11 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 52.5 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →